(Note: Translational Development Acquisition Corp. postponed its SPAC IPO on Tuesday, Sept. 20, 2022; this deal had been expected to price on that date after the market’s close.)

We intend to focus on the healthcare or healthcare-related industries. In particular, we will target North American or European companies in the life sciences and biotechnology sectors where our management has extensive investment experience. We will search for a target company in these sectors with a valuation between $300 million and $500 million. (Incorporated in the Cayman Islands) 

Stone Capital Partners, LLC, is our sponsor. 

(Note: Translational Development Acquisition Corp. filed its S-1 on Aug. 26, 2022, with terms: 15 million units at $10 each to raise $150 million; the company filed confidential IPO documents on June 13, 2022. Each unit consists of one share of common stock and one-half of a warrant. Each whole warrant can be redeemed to buy one share of common stock.)